# Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

> **NCT05040984** · — · UNKNOWN · sponsor: **Far Eastern Memorial Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Overactive Bladder Syndrome

## Interventions

- **DRUG:** Solifenacin Oral Tablet
- **DRUG:** Mirabegron 25mg

## Key facts

- **NCT ID:** NCT05040984
- **Lead sponsor:** Far Eastern Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-30
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040984, "Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05040984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*